Risk-Adapted Melphalan with Stem Cell Transplant (Sct) and Adjuvant Dexamethasone (Dex) +/- Thalidomide (Thal) Achieves Low Treatmentrelated Mortality and High Hematologic Response Rates

Autor:	A Cohen, B Clark, M Stubblefield, P Zhou, S Nimer, L Reich, J Teruya-Feldstein, Martin Fleisher, R Comenzo, H Hassoun, D Filippa
Rok vydání:	2007
Předmět:	Oncology Melphalan medicine.medical_specialty business.industry medicine.medical_treatment Hematologic Response Surgery Thalidomide Internal medicine medicine Stem cell business Adjuvant Dexamethasone medicine.drug
Zdroj:	XIth International Symposium on Amyloidosis
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ec1b2c2200108989021f15fc54eeba79 https://doi.org/10.1201/9781420043358.ch78 Zobrazit plný text záznamu